| Autor: |
Björn Scheffler, Martin Glas, Matthias Simon, Oliver Brüstle, Ulrich Sure, Michael Weller, Guido Reifenberger, Jörg Felsberg, Torsten Pietsch, Frank K.H. van Landeghem, Kathy Keyvani, Tobias Blau, Christel Herold-Mende, Jens T. Siveke, Alexander Roesch, Barbara M. Grüner, Marc Remke, Verena Jendrossek, Johann Matschke, Shruthi Prasad, Igor Cima, Holger Fröhlich, Ashar Ahmad, Timo Wilhelm-Buchstab, Anja Wieland, Franziska K. Lorbeer, Andreas Till, Daniel Trageser, Laurèl Rauschenbach, Sarah Langer, Celia Dobersalske, Pia Berger, Vivien Ullrich, Sied Kebir |
| Rok vydání: |
2023 |
| Popis: |
Extended Data relating to Main Figure 4/Targeting of AKT-driven subclonal progression of ALDH1A1+ cells. A, Collected source data for main Figs. 4B,C,F-H. Left, diagrams: in vitro cell confluence dynamics of paired treatment naive vs. TMZ-related experimental (TMZ→eR; BN46) or clinical (RT/TMZ; BN118, BN123, BN132) relapse patient cells. Monitoring of cell confluence by software-based cell recognition. Assay specified in Fig. 4A. Right, graphs: Readout results from the indicated cases in line, representing source data for Figs. 4B (Cell Confluence), 4C (Cell Viability), and 4H (Apoptosis). Respective assays specified in the main Figure Legends. Data as mean ± SD. p values calculated by pairwise Wilcoxon rank-sum test followed by multiple testing correction using Benjamini-Hochberg method. B, IF of ALDH1A1 and Ki67 in the BN46-donor cell tumor PDX model. Shown is an example from a TMZ+MK2206-treated mouse (OS = 148 days; low levels of cellular co-expression). Scale bar: 20 µm. C, Comparison of overall survival under the investigated treatment conditions (refer to Fig. 4J). Hazard ratio 95% confidence interval estimates and significance levels derived from Cox regression are shown. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
